ArticlePloS one2024
Hematological ratios as an indicator of severity in alopecia areata: A retrospective nationwide study.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Baseline Neutrophil-to-Lymphocyte Ratio Stratifies Early Trichoscopic Response to Platelet-Rich Plasma-Based Regimens in Non-Scarring Alopecia: A Real-World Cohort with Internal Validation Using an Interpretable Neural Network.Life (Basel, Switzerland) · 2026Article
- Longitudinal biomarker trajectories accompanying trichoscopic change after PRP-based regimens for alopecia: a complementary multi-marker analysis of a real-world cohort.Journal of medicine and life · 2026Article
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlopecia Areata (AA) is an autoimmune condition where the activation of Th1, Th2, and Th17 responses is known to stimulate other white blood cells, potentially affecting hematopoietic lineages. However, previous studies on AA have found no utility in hematological ratios. Our goals were to compare neutrophils-to-lymphocytes ratio (NLR), platelets-to-lymphocytes ratio (PLR), eosinophils-to-lymphocytes ratio (ELR), eosinophils-to-neutrophils ratio (ENR), and eosinophils-to-monocytes ratio (EMR) between patients with AA and controls, as well as between mild and moderate-severe AA cases. METHODS AND
findingsWe performed a retrospective, population-based cohort study involving adult patients enrolled in the largest national health maintenance organization in Israel. The study comprised 147,020 AA patients and 141,598 healthy controls. AA patients exhibited a higher likelihood of elevated NLR and ELR compared to controls. Upon further classification based on severity, moderate-severe AA patients displayed higher values of NLR, PLR, ELR, and EMR compared to mild AA individuals OR = 1.11 [1.09-1.1], P<0.001; OR = 1.09 [1.05-1.13], P<0.001; OR = 2.06 [1.67-2.53], P<0.001; OR = 1.07 [1.03-1.07)], P<0.001, respectively). Similar trends were observed 12 to 18 months before diagnosis.
conclusionOur results not only deviate from the current literature but also offer a cost-effective, accessible, and efficient tool for enhanced disease prediction and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.